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Abstract
Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is
particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-
inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures
should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella
zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may
pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic
transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to
vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the
postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in
multiple myeloma and provide recommendations for clinical practice.
Introduction
Infections remain the most common cause of morbidity and
mortality in multiple myeloma besides the disease itself [1, 2].
The risk of infection is increased already at the stage of
MGUS [3], and is even higher in patients with active disease
when starting anti-myeloma therapy. One population-based
study has estimated a tenfold higher risk for viral and a
sevenfold higher risk for bacterial infections in multiple
myeloma [4]. Severe humoral and cellular immune suppres-
sion, particularly during episodes of uncontrolled disease,
account mainly for the increased susceptibility for infections.
This predisposition is aggravated by the negative con-
sequences of anti-myeloma therapy associated with severe
immune suppression including impaired T-cell function and
antibody production. Sensitizing the patient’s own immune
system against frequent pathogens by vaccination during
phases with no or little immunosuppression seems a logical
approach in curbing the infection risk. Here, we review the
risk of myeloma patients for infections possibly preventable
by vaccinations, the available vaccines, their benefits and
limitations, and provide recommendations for clinical practice.
Methodology
Relevant literature published after 2000 was identified and
reviewed using Medline, Cancerlit, and the Cochrane library.
Recent studies presented at ASH, EHA, and EBMT were
additionally taken into account. Following data extraction and
assessment, a preliminary version was generated and revised
by the authors. Comments and suggestions have been incor-
porated in the paper resulting in a final version, which has
been approved by all authors.
Vaccination studies in myeloma are limited often by
small numbers of enrolled patients and by laboratory
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outcome measures, which usually consist of evaluation of
antibody titers only, and less frequently by proving clinical
effectiveness (Table 1). Moreover, several recommenda-
tions are made in analogy to those made for the general
population, or for similar diseases. International institutions,
such as the center of disease control and prevention (CDC)
[5], the World Health Organization (WHO) [6], or profes-
sional societies such as National Comprehensive Cancer
Network (NCCN®) [7] and other published recommenda-
tions for vaccinations, either for the general population, for
people aged 65 or older, for patients with impaired immune
system [5], or for patients treated with autologous or allo-
geneic stem cell transplantation [7]. We needed to abstain
from grading the recommendations for their strength of
evidence, as suggested by the European Society of Micro-
biology and Infectious Disease [8], because of lack of data
from randomized trials in patients with multiple myeloma.
This is in accordance with a recent critical review of the
Infectious Disease Society of America (IDSA) pointing to
the suboptimal strength of scientific evidence for the
majority of recommendations, which nevertheless are based
on observational studies, clinical experience, and reports of
expert committees [9].
Immune suppression in multiple myeloma
Efficient anti-infective defense requires a complex interplay
between antigen recognition, antibody response, cellular
defense, and humoral factors such as complement.
Depressed antibody production against common pathogens
has been documented in MGUS patients and is even more
pronounced in patients with multiple myeloma, and parti-
cularly in those with active disease [10]. The immune
dysfunction is further aggravated by varying degrees of
lymphopenia, neutropenia, and reduced opsonization and
functional impairment of phagocytosis and intracellular
killing [10]. Myeloma therapy frequently contributes to
cytopenia and immune suppression and may lead to sig-
nificant disruption of mucosal barriers. Immune senescence
may add to immune deficiency in the majority of myeloma
patients diagnosed at higher age, as both antibody and




Influenza virus usually is transmitted through droplets and
contact with contaminated surfaces. A person may be
infectious before and during symptoms. Influenza spreads
around the world in yearly outbreaks, resulting in about
three to five million cases of severe illness and about
290,000–650,000 deaths, particularly in young children and
in elderly people [13], especially in those with comorbid-
ities or severe immunosuppression. Hemagglutinin and
neuraminidase expressed on the membrane of influenza
virus are important targets of vaccines, because the former
mediates binding of virus to target cells and entry into their
genome, and the latter promotes binding to target cells and
the release of progeny virus from infected cells [14].
Influenza viruses show a high mutational activity, which
requires adaptation of the composition of vaccines in yearly
intervals. The trivalent influenza vaccines comprise two
serotypes of influenza A and one of influenza B. The
quadrivalent vaccine comprises a second serotype of influ-
enza B. Vaccination with influenza induces a humoral
immune response against hemagglutinin and less pro-
nounced against neuraminidase glycoproteins [15], parti-
cularly the latter protect against intracellular uptake when
exposed to the same virus type [16]. Although exposure to
live influenza virus creates a strong CD4 T-cell effector
response, vaccines usually elicit poor cellular immunity
[17]. Clinical studies show seroconversion after vaccination
in about 70–80% of patients with malignancies [18, 19] and
a Cochrane review on 2275 patients with malignancies
revealed a significant, albeit limited reduction in mortality
in cancer patients receiving different types of influenza
vaccines [20]. In myeloma, a study published two decades
ago reported poor response to influenza vaccine [21]. Only
19% of patients developed protective antibody titers to all
three strains and 10% against two viral strains of the vac-
cine. In another study in patients with solid tumors and
hematologic malignancies including 15 patients with mul-
tiple myeloma, protective titers were obtained in 27% of
patients [22], with little further increase after a second
boost. However, it is unclear whether a hemagglutinin titer
of 1:40 is the right cutoff distinguishing between a clinically
relevant protection or not. A more recent study by Hahn
et al. [23] showed preexisting humoral immunity against
one or more influenza serotypes in 9–19% of the patients.
After a single vaccination, the frequency of patients with
‘sufficient’ titers to one strain rose by 20–40%. After a
second vaccine boost, the number of patients with assumed
protective titers nearly doubled. Two doses of influenza
vaccine were automatically given 30 days apart in another
study [24]. Rates of seroprotection against all three strains
increased from baseline 4% to 49%, and 65% following
one, and two doses, respectively [24]. Hence, as influenza
antibody testing with the hemagglutination inhibition assay
is not established as routine procedure, we recommend that
patients without documented immune response should
automatically be vaccinated twice within a 4-week interval
[25]. No correlation between myeloma therapy or treatment
intensity, and seroconversion has been observed in the


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































34 H. Ludwig et al.
study by Nordoy [18], while in the study by Branagan et al.
[24] active disease requiring therapy, less than partial
response, and conventional chemotherapy were associated
with lower likelihood for a serological response.
Vaccination with trivalent and the newer quadrivalent
influenza vaccines is recommended for all patients with
MGUS, SMM, and multiple myeloma, their family mem-
bers and their care givers [26]. The recommendation for
patients is supported by WHO [27], CDC [28] and by
NCCN® [29], all of them propose influenza vaccinations in
immunocompromised individuals (Table 2). Vaccinating
health care providers in long-term care units is supported by
the WHO [30], the CDC [31], and by data from a recent
review [32], but studies documenting a significant benefit in
acute care units are not available. The vaccination should be
planned before the start of treatment [33] and before the
beginning of a new influenza season, or in a period after the
end of treatment with deep response to myeloma therapy.
Varicella zoster
Patients treated with proteasome inhibitors [2], dar-
atumumab [34], high-dose melphalan followed by auto-
logous stem cell transplantation (ASCT) [2], and high doses
of glucocorticosteroids [2] have a higher risk for varicella
zoster virus (VZV) reactivation. Reactivation of latent virus
residing in sensory ganglions leads to active virus produc-
tion, spread alongside the axons down to the area of skin
innervated by that ganglion, inflammation, blisters, and pain
[35]. One large study on 9253 myeloma patients reported a
hazard ratio of 14.8 for VZV reactivation compared to the
general population [4]. Vaccines consisting of live-
attenuated herpes virus [36], although found to be safe
and active in myeloma patients, were generally not
recommended in patients with multiple myeloma with fre-
quently impaired immune system. Inactivation of VZV
precludes any potential risk of reinfection. A recent ran-
domized study with a gamma-irradiated and thereby inac-
tivated VZV vaccine was found active in a large group,
including around 45% with myeloma of autologous stem
cell transplant recipients, dosed once 5–60 days before and
three times (30, 60, and 90 days) after ASCT. The vacci-
nation reduced VZV reactivations (8 vs. 21%) significantly
during a 2.3–2.4 year follow-up period) and postherpetic
complications. The vaccine was safe with no difference in
AEs other than in local injection site reactions [37]. A new
adjuvanted recombinant VZV glycoprotein E vaccine
reduced the risk for VZV reactivation by 97% in elderly
individuals of the general population and was well tolerated
[38]. A trial with two doses of this vaccine in patients with
hematological malignances, including 132 patients with
multiple myeloma during or after immunosuppressive
therapy, showed a humoral immune response in 80.2% of
vaccinated patients with practicably no conversion (0.8%)
in those receiving placebo [39]. Only two patients of the
active study drug group developed VZV reactivation, as
compared to 14 of the placebo arm during a 13 months
follow-up period.
Based on these results, a proactive position favoring the
use of the recombinant VZV glycoprotein E vaccine over the
live-attenuated VZV vaccine seems justified practically in all
patients with multiple myeloma, as many of them will receive
ASCT and almost all treatment with immunosuppressive
drugs. Patients should receive two doses 2–6 months apart.
This strategy should be complemented by conventional pro-
phylaxis with acyclovir or valaciclovir for further risk
reduction. This is of particular importance in patients
receiving proteasome inhibitors, or anti-CD38 antibodies.
Hepatitis A virus
Vaccination with an inactivated hepatitis A vaccine is
recommended in nonimmune patients traveling to endemic
regions (Southeast Asia, Mediterranean countries, Africa,
Middle and South America). Patients should receive two
doses given at least 6 months apart to achieve long lasting
protection [40], which can be attained in up to 95% of the
general population. Prophylaxis with intravenous immu-
noglobulins is an alternative option for those exposed for
only a limited period. Protective anti-hepatitis A antibody
titers have been detected in all five immunoglobulin pro-
ducts tested [41, 42].
Hepatitis B virus
Patients planned for therapy with proteasome inhibitors,
immunomodulatory drugs, high-dose dexamethasone,
monoclonal antibodies, and/or stem cell transplantation
should be screened for hepatitis B by testing for HBs-Ag
and anti-HBc antibodies [43]. In case of negative HBs-Ag
and positive anti-HBc results, patients should be tested for
hepatitis B DNA. In patients without evidence of hepatitis B
infection, no further action is needed unless the patient lives
in, or travels to, areas endemic for hepatitis B or patients
who have sexual partners with chronic hepatitis B infection.
In those individuals, vaccination with hepatitis B is
recommended. In case of HBs-Ag positivity and/or positive
hepatitis B DNA, antiviral therapy should be administered
[41] concomitantly to anti-myeloma treatments with sig-
nificant T-cell immunosuppressive activity. The third gen-
eration antiviral nucleoside analogues entecavir or
tenofovir, are highly active, with almost no risk for devel-
oping resistance and are well tolerated, and thus recom-
mended for those patients [44, 45]. Antiviral prophylaxis
should be continued for several months and preferably until
completion of anti-myeloma therapy, but exact figures from





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































36 H. Ludwig et al.
randomized trials are not available. Up to now, the newer
and possibly more potent antiviral drugs such as entecavir,
adefovir or tenofovir have not systematically been studied
in multiple myeloma, but it can be anticipated that those
new drugs will be associated with a lower risk for resistance
development.
Hepatitis C virus
The same diagnostic procedures recommended for patients
subjected to highly immunosuppressive therapy should be
applied for hepatitis C screening. Patients with detectable
disease documented by hepatitis C virus RNA should
receive therapy with direct-acting antivirals, if possible
before start of myeloma therapy. In spite of intensive
research, there is no vaccine available today [46].
Measles, mumps, and rubella
Vaccination against measles, mumps, and rubella (MMR) is
routinely provided by most health care systems of devel-
oped countries and there are no reports indicating that
patients with multiple myeloma are at greater risk than the
general population to develop clinically relevant disease
induced by the aforementioned viruses. MMR vaccination
usually leads to live long protection, but antibody levels and
avidity may wane by up to 25% after 20 years of follow-up
[47]. Nevertheless, after allogeneic transplantation, the
probability of becoming seronegative was 60% for measles,
73% for mumps, and 52% for rubella in one study [48],
which mandates either revaccination of those patients after a
safety time period (>24 months) after transplantation or
antibody testing against these viruses. Current available
vaccines are live-attenuated and should not be used during
the first 2 years following ASCT [49].
Bacteria
Pneumococci
Streptococcus pneumonia species are common members of
the bacterial flora colonizing the mouth and throat in 5–10%
of healthy individuals and are a leading cause of pneumonia,
otitis media, blood stream infection including sepsis and
bacterial meningitis. The risk for developing a pneumo-
coccal infection is increased in individuals with reduced IgG
synthesis, impaired phagocytosis and defective bacterial
clearance and higher age [50]. Over 90 serotypes have been
identified [51], and two types of vaccines are commonly
used to protect against the most important serotypes. The
conjugate PCV13 (13-valent pneumococcal conjugate vac-
cine) vaccine contains purified capsular polysaccharide from
13 serologic strains conjugated to a mutant of diphtheria
toxoid (CRM197). The coupling of the T-cell independent
pneumococcal polysaccharide antigens to a carrier protein
transforms them into T-cell dependent antigens [52] that are
more immunogenic than those of the polysaccharide vaccine
PV23. This latter vaccine induces antibody production in a
T-cell independent manner by acting directly on B cells
resulting usually in less efficient antibody production com-
pared to T-cell dependent PCV vaccines.
Pneumococci vaccines have been evaluated in the gen-
eral population, and in MGUS, SMM, and MM patients. A
large randomized study employing a PCV13 vaccine
showed 45% fewer episodes of vaccine-type community-
associated pneumonia and invasive infections in adults aged
≥65 years [53]. Subsequent to this finding, conjugate vac-
cines have become the vaccine of choice in elderly indivi-
duals. In myeloma patients, substantial antibody responses
were observed in about 30–60% of cases to either PCV13 or
PPSV23 vaccines. In one study, a response to PV23 vac-
cination before ASCT was noted in 33% of patients, with a
response rate of 73% in those who achieved a CR [54].
Similarly, in another trial, higher antibody responses were
reported in patients with well-controlled disease, but anti-
body titers decreased within few months in most patients
[52], an observation reported in another series as well [55].
In MGUS, a high response rate to a PCV13 vaccine was
found [56], and in one of these studies, a reasonable cor-
relation between IgG antibody response to four serotypes
and opsonophagocytic capacity, but this correlation was not
seen in patients with MM [57], where IgG antibodies
without opsonophagocytic capacity were observed as well
[10]. A study in elderly individuals of the general popula-
tion aged 70 years or older showed that antibody response
to several serotypes can be boosted by using higher doses of
PCV7, but this benefit was associated with more adverse
events [58], and data supporting this strategy in patients
with multiple myeloma are not available as yet. As both
PCV13 and PPSV23 vaccine were found to protect against
pneumococcal disease in the general population [59, 60],
patients should be vaccinated with PCV13 (in case of no
previous PCV13 vaccination) followed by PCV23 after
2 months or an even longer interval. PPSV23 vaccination
should be repeated in 5-year intervals but antibody response
to a boost with PPSV23 may be lower than after primary
vaccination [51].
Haemophilus influenzae
Haemophilus influenzae is a common gram-negative
human-restricted bacterial pathogen that frequently colo-
nizes the nasopharynx. It can cause local infections, such as
otitis media and sinusitis and after breaching the epithelial
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barriers, it can result in invasive disease, including pneu-
monia, meningitis, and sepsis [61]. More than 50% of
patients with MM lack protective anti-haemophilus influ-
enzae (Hib) antibodies and serum bactericidal activity
against Hib is absent in 70% of patients [62]. Vaccination
with haemophilus influenzae is recommended in all patients
with asplenia and should be considered in patients with
MM, although data on the clinical efficacy are limited. One
study showed antibody response in 71% of patients vacci-
nated after ASCT [63].
Meningococci
Low immunoglobulin levels, complement deficiencies,
asplenia, and the diagnosis of multiple myeloma are among
other well established risk factors for meningococcal dis-
ease [64]. One study reported a hazard ratio of 16.6 for
patients with MM for developing meningococcal disease
compared to controls [2].
Tetravalent capsular polysaccharide conjugate vaccines
with improved immunogenicity targeting serotypes A,C,Y,
W-135, and protein-based, capsular polysaccharide-free
recombinant vaccines targeting serogroup B [64] are
available for clinical use. The latter are now widely used for
population vaccination programs as serogroup B accounts
for the majority of cases [65].
An expert group [8] recommended to use the con-
jugated tetravalent conjugated vaccine and to consider
vaccination against serogroup B as well in asplenic
patients with hematological diseases. This seems reason-
able in patients with MM in general, and particularly in
those with splenectomy [66], complement deficiency and
possibly also in the post-hematopoietic stem cell trans-
plant setting.
Diphteria, pertussis, tetanus, and polio
Data on the relevance of vaccination with these pathogens
are scarce in conventionally treated patients with MM. In
lymphoma and AML patients, significantly more patients
lacked protective antibody titers against tetanus and
diphtheria after intensive therapy [67]. In patients
receiving an allotransplantation a significant loss of anti-
body protection against tetanus and polio was reported
[68, 69]. Pertussis may cause infections in adults, but data
on reappearance of pertussis in myeloma patients are
limited; noteworthy, protective antibody titers often are
decreased in patients after allotransplantation [70].
Overall, there is little information on the immunity against
these pathogens in myeloma patients, but vaccination with
these antigens is recommended in patients after allogeneic
transplantation.
Autologous and allogeneic transplantation
Antibodies for various pathogens including pneumococci,
haemophilus, and measles are significantly reduced after
autologous [71, 72] and more so after allogeneic stem cell
transplantation [73]. Transplanted patients have a higher risk
for virus reactivation and develop a more severe course of
viral infections [74]. These and other findings prompted the
IDSA to consider recipients of allotransplantation as never
vaccinated [75], highlighting the need for a full vaccination
program. Several recommendations have been published by
international and national societies for patients after stem cell
transplantation [48, 49]. The NCCN® Guidelines for patients
after autologous and allogeneic stem cell transplantation are
shown in Table 3. Patients should be vaccinated with vaccines
administered during early childhood, and pneumococci,
haemophilus influenzae and meningococci, influenza and
recombinant VZV vaccine [29]. Due to the poor immune
response after allogeneic transplantation, vaccination should
be repeated in short intervals (4-week intervals) for most
pathogens. The CDC recommends vaccination with MMR in
patients 24 months after allogeneic transplantation and with-
out signs of graft versus host disease [5]. There is some
inconsistency regarding the appropriate timing of the vacci-
nations. As patients are prone to increased infection risk
shortly after transplantation, some experts recommend to
administer seasonal influenza vaccine already a few months
after ASCT. A second vaccination should be considered to
increase antibody response [76]. Timing vaccination relatively
early after transplantation is supported by data showing
comparable response rates to PCV vaccination in patients
who were vaccinated 3 or 9 months after the transplant [77].
Hence, there are relevant arguments for starting some vacci-
nations, like influenza and PCV13, already about 3 months
after autologous transplantation, but it should be kept in mind
that official organizations take a more conservative approach
favoring a longer interval between autologous transplantation
and vaccination as shown in Table 3 [29].
Monoclonal antibodies, T-cell engagers (BiTEs), CAR-T cells
A small series of patients with RRMM treated with dar-
atumumab showed a similar vaccination response to PCV13
and PPV23, Haemophilus influenza, and seasonal influenza
compared to patients receiving non-daratumumab contain-
ing regimes [78]. Similar responses likely are to be expected
for other CD38 monoclonal antibodies. No information is
available for the other above-mentioned treatments. Patients
subjected to treatment with BiTEs or CAR-T cells usually
are heavily pretreated and often present with severely
compromised bone marrow reserve and long lasting
impairment of anti-infective immune response. Ideally,
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patients should be vaccinated before start of rescue therapy
with the entire spectrum of vaccines listed in Table 2, with
influenza, VZV, and vaccination against encapsulated bac-
teria (pneumococci, haemophilus influenzae, and menin-
gococci) being most important.
Disease status and vaccination
Common reasoning suggests that patients should be vac-
cinated before transformation into active myeloma at
MGUS or SMM stage, or during remission when there is
no or only minor immune suppression by active disease,
but scientific support for this notion is available in CLL
patients only [79]. Limited evidence suggests that patients
on lenalidomide maintenance show an enhanced antibody
response from the immune stimulatory effects induced by
IMiDs [80], but a recent study in patients on lenalidomide
maintenance was unable to confirm this [63]. In patients on
daratumumab therapy, a similar vaccination response was
reported compared to patients receiving non-daratumumab
containing therapy [78]. Patients with scheduled che-
motherapy should be vaccinated at least 2 weeks before
initiation of chemotherapy [5], upon achievement of best
response, 3–6 months after completion of chemotherapy or
autologous transplantation, and 6–24 months after allo-
geneic transplantation. Vaccination with inactivated or live
Table 3 Recommended vaccination schedule after autologous or allogeneic HCT (with permission of the NCCN®).
Inactivated vaccinesa Recommended timing after HCT Number of doses
DTaP (diphtheria/tetanus/acellular pertussis) 6–12 months 3
Pneumococcal vaccination
• Conjugated 13-valent vaccine 6–12 months 3
• Upon completion of PCV13 series, then PPSV23 ≥12 months 1
Hepatitis Ab (Hep A) 6–12 months 2
Hepatitis Bb (Hep B) 6–12 months 3
Meningococcal conjugate vaccinec 6–12 months 1–2
Influenza (injectable)d 4–6 months 1d, annually
Inactivated polio vaccine 6–12 months 3
Recombinant zoster vaccine 50–70 days after autologous HCT
May be considered after allogeneic HCTe
2
Human papillomavirus (HPV) vaccine >6–12 months
For patients up to age 26, consider up to age 45
3
Live vaccines Recommended timing after HCT Number of doses
Measles/mumps/rubella (MMR)f ≥24 months
(if no GVHD or ongoing immunosuppression and patient
is seronegative for measles, mumps, and/or rubella)
1–2
Varicella vaccinef ≥24 months
(if no GVHD or ongoing immunosuppression and patient
is seronegative for varicella)
1
Zoster vaccinef,g (category 3) May be considered at ≥24 months
(if no GVHD or ongoing immunosuppression)
1
Reproduced with permission from the NCCN Guidelines® for prevention and treatment of cancer-related infections V.1.2020. ©2019 National
Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for
any purpose without the express written.
aInactivated vaccines may be given as a combined vaccine. Vaccination may be postponed for patients receiving >20 mg of prednisone.
bStrongly consider if clinically indicated. May consider Hep A and B combined vaccine if immunization for both is needed.
cMeningococcal B vaccine should be considered for high-risk patients such as patients with asplenia or complement deficiency or patients
receiving eculizumab.
dAs antibody response may be suboptimal, EMN recommends a second administration, or confirmation of antibody response by adequate testing.
eEfficacy in allogeneic HCT, in the presence of GVHD, or ongoing immunosuppression has not been established (Bastidas A, et al. JAMA.
2019;322:123–33).
fMMR and varicella/zoster vaccines may be given together or 4 weeks apart.
gBecause of insufficient data on safety and efficacy of live zoster vaccine among HCT recipients, physicians should assess the immune status of
each recipient on a case-by-case basis and determine the risk for infection before using the vaccine. Randomized data exist for use of the
recombinant zoster vaccine in patients receiving autologous HCTs but not for the live zoster vaccine.
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vaccines should not be given either before or about
3 months after treatment with intravenous immunoglobulin
therapy because of concerns about effectiveness of vac-
cines [5].
Family members, close patient contacts, and health care
workers
Persons in close contact with the patient should receive all
age- and exposure appropriate vaccines and should speci-
fically be vaccinated against influenza, and those aged 65
years or older against pneumococci (Table 4). Patient con-
tacts should be aware that there is a small risk of transfer-
ring live vaccines with the exception of MMR [5] to the
patient. Studies from several countries show significant
immunity gaps against many vaccine-preventable diseases
in health care providers highlighting the need for uniform
recommendation. Immunity against the spectrum of patho-
gens vaccinated against during childhood should be ascer-
tained. This is particularly relevant for mumps, rubella, and
measles [81, 82]. In case of inadequate antibody response,
revaccination is recommended. In addition, health care
workers should be vaccinated against hepatitis B, and reg-
ularly against influenzae, and depending on specific situa-
tions against other pathogens listed in Table 4.
Contraindications, precautions, and side effects
Severely immunosuppressed patients should not receive
live vaccines. Myeloma patients, if not in sustained well-
controlled remission, are considered immunosuppressed,
and thus are not candidates for life vaccines. Vaccination
should also be withheld in an individual who had a severe
allergic reaction after a previous dose or vaccine compo-
nent. Vaccination should be deferred in patients with
uncontrolled disease, ongoing infections, or other acute
illnesses. Presently, there are no contraindications for
vaccinating patients with a previous episode of infection
with the same class of pathogens the vaccine should pro-
vide protection for. For example, vaccination with PCV13
is recommended in a patient even if he had a previous
episode of pneumococcal pneumonia, because the vaccine
contains serotypes the patient might not have been
exposed to.
Modern vaccines usually are very well tolerated. Local
reactions, such as areas of redness, swelling, pain, and infre-
quently induration, may occur at the injection site. Such
reactions may increase in severity with each subsequent
injection. Very rarely, general reactions such as fever, chills,
feeling tired, headache, muscle and joint aches are encoun-
tered. Neurological side effects, including Guillain–Barre
syndrome (after influenza vaccination), anaphylaxis, bronch-
ospasm, laryngeal edema, generalized collapse, and prolonged
unresponsiveness have previously been reported as very rare
complications with an incidence of about 1/1,000,000 [83, 84].
Limitations
Many of the available data have been published before the
introduction of novel myeloma drugs and treatment strategies,
which nowadays result in higher response rates and deeper
Table 4 Recommendations for vaccination of family members and for health care personnel.
Vaccine Dose Family member Health care personnel Supported by
Influenzae One dose, assess response and repeat if insufficient
(or use two doses without response assessment)
+++ +++ CDC
Hepatitis A One dose, administer booster dose 6–36 months later Only if traveling to endemic areas +
Hepatitis B One dose, assess response within 1–6 months, or
administer three doses without assessment
If patient has active diseasea or plans traveling
to endemic areas or has a sexual partner with
chronic hepatitis B infection
+++ CDC
Pneumococci PCV13 followed after ≥2 months by PV23 If age 65 years or older If age 50 years or olderb EMN
Meningococci One dose with a booster every 5 years − Personnel handling
N. meningitis specimen
CDC
Varicella Two doses 4 weeks apart − +++




Two doses of recombinant glycoprotein E If age 65 years or older If age 50 years or olderb EMN
Diphtheria, tetanus,
pertussis
One dose if not received in adulthood
Get booster ever 10 years (even if preexisting immunity)
+
If no preexisting immunity
+++




Two doses if no evidence of immunity +
If no preexisting immunity
+++
If no preexisting immunity
CDC
aHBV-DNA, HBs-AG, or HBe-Ag positive.
bMay be considered, CDC Center of Disease Control, NCCN National Comprehensive Cancer Network, EMN European Myeloma Network,
− not recommended, + recommended, +++ highly recommended.
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responses, reducing or even obviating myeloma induced
immune suppression. Several studies included small patient
numbers, making it difficult to evaluate the validity of their
findings. Almost all studies reporting response to vaccination
provide data on antibody response only; there is no validation
whether a rise in antibody titer to ≥1:40 correlates with the
assumed clinical protection, nor are data available on the
impact of opsonophagocytic activity on clinical efficacy.
Cellular immunity is usually not assessed. Randomized trials
providing the scientific evidence for vaccination recommen-
dations in multiple myeloma are available for a few indica-
tions only; most of the recommendations rely on clinical
observations, consensus of experts, published by international
or national societies, observational studies, and on analo-
gies drawn from the general population. In spite of these
limitations, thorough review of the existing data and balancing
the weight of evidence within a group of experts of the disease
likely provides relevant information for clinical care. This was
our main objective, which we hope to have accomplished.
Conclusion
Infections are the second major cause of mortality in multiple
myeloma, mandating optimization of measures for prevention
of infections. Vaccination is one of the greatest achievements
of medical research, which has saved the life of millions of
people, and an effective preventive strategy in patients with
multiple myeloma. Ongoing research has led to the devel-
opment of genetically engineered VZV vaccines obviating the
need of using attenuated live vaccines, and further improve-
ments in efficacy and safety of other vaccines can be expected
for the near future. Still, in real world clinical practice, the
entire potential of a comprehensive vaccination policy is
underused. This work aims to provide the necessary medical
background and recommendations for an optimal vaccination
strategy in myeloma patients likely to benefit from this
important preventive measure.
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